Theravance Reports Third Quarter 2014 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Theravance Reports Third Quarter 2014 Financial Results

SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 30, 2014) - Theravance, Inc. ( NASDAQ : THRX ) today reported financial results for the quarter ended September 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on December 23, 2014 to stockholders of record as of the close of business on November 25, 2014. Royalties received on net sales of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® from Glaxo Group Limited (GSK) were $4.0 million. Net loss for the third quarter of 2014 was $21.3 million or $0.19 per diluted share. Cash, cash equivalents, marketable securities and current restricted cash totaled $316.5 million as of September 30, 2014.

"In the third quarter, we elevated our efforts to work closely with GSK to achieve our goal of optimizing the commercial potential and value of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® as both products continue to launch across the globe," said Michael W. Aguiar, Chief Executive Officer of Theravance. "Today, we announced that Bill Waltrip, who has served as a director since April 2000 and lead independent director since April 2005, was appointed as Chairman of our Board of Directors replacing Rick E Winningham who stepped down from the Board. This represents the final step in the process of separating the governance of Theravance and Theravance Biopharma, Inc. I would like to thank Rick for his contributions, guidance and leadership over the years and look forward to continuing to work closely with Bill going forward."

Corporate Highlights

  • Expanded the Theravance management team through the appointment of Michael Aguiar as Chief Executive Officer and Eric d'Esparbes as Chief Financial Officer.
  • Paid cash dividend of $0.25 per share on September 18, 2014 to stockholders of record as of the close of business on August 28, 2014.
  • Completed the management and governance separation from Theravance Biopharma, Inc. ("Theravance Biopharma") and appointed William H. Waltrip as Chairman of its Board of Directors.

Product Highlights

  • In the third quarter of 2014, GSK achieved product sales of $25.6 million for RELVAR ® /BREO ® ELLIPTA ®  and sales of $1.8 million for ANORO ® ELLIPTA ® .
  • As of September 30, 2014, RELVAR ® /BREO ® ELLIPTA ® has been approved in 53 countries for marketing and has been launched in 30 countries, including the U.S., Canada, U.K., Germany and Japan.
  • As of September 30, 2014, ANORO ® ELLIPTA ® has been approved in 42 countries for marketing and has been launched in 9 countries, including the U.S., Canada, U.K., Germany and Japan.
  • GSK presented data supporting the efficacy and safety of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® during the European Respiratory Society Annual Congress (ERS) that took place in September 2014 in Munich, Germany.
  • Respiratory Medicines published positive results from a lung function study comparing the efficacy and safety of ANORO ® ELLIPTA ® with the LAMA, tiotropium, administered in the HandiHaler ® inhaler, to patients with chronic obstructive pulmonary disease (COPD). In this study, ANORO ® ELLIPTA ® showed statistically significant improvement compared to tiotropium in measurement of lung function using trough forced expiratory volume in one second (FEV 1 ) at the end of the treatment period (day 169). In addition, ANORO ® ELLIPTA ® showed a statistically significant improvement compared to tiotropium in measurement of lung function using weighted mean FEV 1 0 - 6 hour, at the end of the treatment period (day 168). The most commonly reported side effects for both ANORO ® ELLIPTA ® and tiotropium included headache, nasopharyngitis, cough and back pain.
  • GSK presented data from Phase 3 studies at CHEST 2014 in Austin, Texas, held from October 25, 2014 through October 30, 2014: (1) Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) versus fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations; and (2) Efficacy and safety of once-daily umeclidinium added to fluticasone furoate/vilanterol in COPD: Results of two replicate randomized 12-week studies.

Financial Results for the Third Quarter Ended September 30, 2014

On June 1, 2014, Theravance separated its late-stage partnered respiratory assets from its biopharmaceutical research and drug development operations by transferring its research and drug development operations into Theravance Biopharma, a then wholly-owned subsidiary. Theravance contributed $393.0 million of cash, cash equivalents and marketable securities to Theravance Biopharma and all outstanding shares of Theravance Biopharma were then distributed to its stockholders as a pro-rata dividend distribution on June 2, 2014 by issuing one ordinary share of Theravance Biopharma for every 3.5 shares held of Theravance common stock to stockholders of record on May 15, 2014 (the "Spin-Off"). The Spin-Off resulted in Theravance Biopharma operating as an independent, publicly traded company.

The results of operations for Theravance's former research and drug development operations conducted by it and by Theravance Biopharma until June 1, 2014 are included as part of the condensed consolidated statement of income as discontinued operations.

Total net revenue for the third quarter 2014 was $1.0 million, which resulted from net royalties of $4.0 million from net sales of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® and $0.3 million from revenue from collaborations which was partially offset by amortization of intangible assets of approximately $3.2 million. The majority of royalties were driven by sales of RELVAR ® /BREO ® ELLIPTA ® .

Research and development expenses for the third quarter of 2014 were $1.9 million compared with $2.1 million for the same period in 2013. The decrease in the third quarter compared to the same period last year was primarily due to the reduced level of operations as a result of the Spin-Off. Total research and development stock-based compensation expense for the third quarter of 2014 was $1.4 million, compared with $0.1 million for the same period in 2013.

General and administrative expenses for the third quarter of 2014 were $8.6 million compared with $6.0 million for the same period in 2013. The increase in the quarter compared to the same period last year was primarily due to the recognition of higher stock-based compensation expense and employee-related costs, outside services and one time costs, primarily associated with post Spin-Off transition activities. Total general and administrative stock-based compensation expense for the third quarter of 2014 was $3.4 million compared with $1.9 million for the same period in 2013.

Cash, cash equivalents, short-term investments, marketable securities and restricted cash totaled $316.5 million as of September 30, 2014 compared with a balance of $383.0 million as of June 30, 2014, a decrease of approximately $66.5 million. The decrease was primarily due to cash used in operations, dividends paid, launch-related payments to GSK, and a final payment to Theravance Biopharma associated with pre-Spin-Off obligations, partially offset by royalties received from GSK and net proceeds received from issuances of Theravance common stock.

The Board of Directors approved a $0.25 per share cash dividend to be paid on December 23, 2014 to stockholders of record as of the close of business on November 25, 2014.

Conference Call and Webcast Information

As previously announced, Theravance has scheduled a conference call and webcast to discuss this announcement beginning at 5:00 p.m. Eastern Daylight Time today. To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting Theravance's website at www.thrxinc.com . To listen to the live call via the Internet, please go to the website 15 minutes prior to its start to register, download, and install any necessary audio software.

A replay of the conference call will be available on Theravance's website for 30 days through November 29, 2014. An audio replay will also be available through 11:59 p.m. Eastern Standard Time on November 6, 2014 by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers, and entering confirmation code 18386593.

About Theravance

Theravance, Inc. is focused on maximizing the potential value of the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® , with the intention of providing capital returns to stockholders. Under the Long-Acting Beta 2 Agonist (LABA) Collaboration Agreement with GSK, Theravance is eligible to receive the associated royalty revenues from RELVAR ® /BREO ® ELLIPTA ® (fluticasone furoate/vilanterol, "FF/VI"), ANORO ® ELLIPTA ® (umeclidinium bromide/vilanterol, "UMEC/VI") and if approved and commercialized, VI monotherapy. Theravance is also entitled to a 15% economic interest in any future payments made by GSK under agreements entered into prior to the spin-off of Theravance Biopharma, and since assigned to Theravance Respiratory Company, LLC, relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta 2 Agonist (MABA) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under these agreements with GSK (other than RELVAR ® /BREO ® ELLIPTA ® , ANORO ® ELLIPTA ® and VI monotherapy). For more information, please visit Theravance's web site at www.thrxinc.com .

RELVAR ® , BREO ® , ANORO ® , and ELLIPTA ® are trademarks of the GlaxoSmithKline group of companies.

Forward Looking Statements

This press release contains and the conference call will contain certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Theravance intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks, uncertainties and assumptions. Examples of such statements include statements relating to: the commercialization of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® in the jurisdictions in which these products have been approved, the strategies, plans and objectives of the company, the timing, manner, amount and planned growth of anticipated potential capital returns to stockholders (including without limitation statements, expectations of future cash dividends and the potential for future share repurchases), the status and timing of clinical studies, data analysis and communication of results, the potential benefits and mechanisms of action of product candidates, expectations for product candidates through development and commercialization, the timing of seeking regulatory approval of product candidates, and projections of revenue, expenses and other financial items. These statements are based on the current estimates and assumptions of the management of Theravance as of the date of this press release and the conference call and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: the disruption of operations during the transition period following the spin-off, including the diversion of managements' and employees' attention, disruption of relationships with collaborators and increased employee turnover, lower than expected future royalty revenue from respiratory products partnered with GSK, delays or difficulties in commencing or completing clinical studies, the potential that results from clinical or non-clinical studies indicate product candidates are unsafe or ineffective, dependence on third parties to conduct its clinical studies, delays or failure to achieve and maintain regulatory approvals for product candidates, and risks of collaborating with third parties to discover, develop and commercialize products. Other risks affecting Theravance are described under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" contained in Theravance's Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 filed with the Securities and Exchange Commission (SEC) on August 7, 2014. Additional information will also be set forth in those sections of Theravance's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, which will be filed with the SEC in the fourth quarter of 2014. In addition to the risks described above and in Theravance's other filings with the SEC, other unknown or unpredictable factors also could affect Theravance's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

(THRX-F)

   
THERAVANCE, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(In thousands, except per share data)  
   
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2014     2013     2014     2013  
    (unaudited)     (unaudited)  
Revenue:                                
  Net royalty revenue   $ 729     $ --     $ 342     $ --  
  Net revenue from collaborative arrangements from a related party     270       415       811       3,059  
    Total net revenue (1)     999       415       1,153       3,059  
                                 
Operating expenses:                                
  Research and development (2)     1,909       2,104       6,721       6,555  
  General and administrative (2)     8,632       6,018       28,491       17,882  
    Total operating expenses     10,541       8,122       35,212       24,437  
                                 
Loss from operations     (9,542 )     (7,707 )     (34,059 )     (21,378 )
                                 
Other income (expense), net     255       (37 )     335       6,734  
Interest income     93       192       446       567  
Interest expense     (12,355 )     (1,902 )     (24,326 )     (7,662 )
  Loss from continuing operations before income taxes     (21,549 )     (9,454 )     (57,604 )     (21,739 )
Income tax     278       --       --       --  
  Loss from continuing operations, net of tax     (21,271 )     (9,454 )     (57,604 )     (21,739 )
  Loss from discontinued operations     --       (37,531 )     (94,934 )     (99,033 )
                                 
Net loss   $ (21,271 )   $ (46,985 )   $ (152,538 )   $ (120,772 )
                                 
Basic and diluted net loss per share:                                
  Continuing operations, net of tax   $ (0.19 )   $ (0.09 )   $ (0.52 )   $ (0.21 )
  Discontinued operations     --       (0.35 )     (0.85 )     (0.99 )
    Basic and diluted net loss per share   $ (0.19 )   $ (0.44 )   $ (1.37 )   $ (1.20 )
                                 
Cash dividends declared per common share   $ 0.25     $ --     $ 0.25     $ --  
                                 
Shares used to compute basic and diluted net loss per share     113,100       106,295       111,306       100,321  
                                 
                                 
                                 
(1) Net revenue is comprised of the following (in thousands):
 
    Three Months Ended September 30,   Nine Months Ended September 30,
    2014     2013   2014     2013
    (unaudited)   (unaudited)
                             
Royalty revenue   $ 3,962     $ --   $ 7,953     $ --
Amortization of intangible assets     (3,233 )     --     (7,611 )     --
  Net royalty revenue     729       --     342       --
LABA collaboration     --       --     --       1,814
Strategic alliance - MABA program license     270       415     811       1,245
  Total net revenue from GSK   $ 999     $ 415   $ 1,153     $ 3,059
                               
                               
(2) Amounts include stock-based compensation expense for the three and nine months ended September 30 as follows (in thousands):
 
    Three Months Ended September 30,   Nine Months Ended September 30,
    2014   2013   2014   2013
    (unaudited)   (unaudited)
                         
Research and development   $ 1,357   $ 118   $ 2,589   $ 426
General and administrative     3,375     1,850     11,795     5,445
Discontinued operations     --     4,478     11,629     13,833
  Total stock-based compensation expense   $ 4,732   $ 6,446   $ 26,013   $ 19,704
                           
                           
                           
THERAVANCE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
 
    September 30,     December 31,
    2014     2013
    (unaudited)     (1)
               
Assets              
  Cash, cash equivalents and marketable securities   $ 310,863     $ 520,499
  Other current assets     11,193       8,500
  Inventories     --       10,406
  Property and equipment, net     64       10,238
  Intangible assets, net     211,646       124,257
  Other assets     19,947       7,355
    Total assets   $ 553,713     $ 681,255
               
               
Liabilities and stockholders' (deficit) equity              
  Other current liabilities (2)   $ 26,098     $ 44,404
  Payable to a related party     10,000       40,000
  Deferred revenue, non-current     4,058       5,455
  Convertible subordinated notes     255,109       287,500
  Non-recourse notes payable, due 2029     450,000       --
  Other long-term liabilities     1,584       4,774
  Stockholders' (deficit) equity     (193,136 )     299,122
    Total liabilities and stockholders' (deficit) equity   $ 553,713     $ 681,255
                   
(1)   The condensed consolidated balance sheet amounts at December 31, 2013 are derived from audited financial statements.
     
(2)   Amounts include current portion of deferred revenue of $1.1 million and $9.3 million as of September 30, 2014 and December 31, 2013, respectively.
     

Contact Information: Michael W. Aguiar Chief Executive Officer 650-238-9640 investor.relations@thrxinc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 167

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 86

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 78

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 81

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 99

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 50

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 16

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 5

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 55

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 17

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading

Top 5 Most Recently Viewed Articles

GrandCare Health Services Enhances Revenue with Smart Solutions

Updated Category News Views 120

GrandCare Health Services Takes a New Approach to Revenue Management In a strategic move to enhance its financial efficiency, GrandCare Health Services has recently partnered with Homecare Homebase (HCHB), a leading provider of cloud-based technological solutions designed for home health agencies. This collaboration specifically focuses on optimizing revenue cycle...

Continue Reading
Westland Insurance Expands its Ontario Footprint with Acquisition

Updated Category News Views 216

Westland Insurance Expands its Ontario Presence Westland Insurance, a prominent name in Canada’s insurance market, has made strides in enhancing its reach with the acquisition of Paul Ayotte Insurance Brokers Ltd. This strategic move aims to solidify Westland’s footprint in Ontario, allowing for improved service delivery to local clients. This acquisition not only...

Continue Reading
First Industrial Realty Trust Set for Q3 Results Conference Call

Updated Category News Views 50

First Industrial Realty Trust, Inc. (NYSE: FR) faced a pivotal moment back in late 2024, gearing up to unveil its third-quarter numbers. The desks were buzzing as traders anticipated this call—a regular event but always loaded with potential surprises. Q3 Results Anticipation: Supply Chain Stakes or Investor Optimism? On that Thursday morning, scheduled for 10:00 a.m....

Continue Reading
Fannie Mae Panel Predicts Slowdown in Future Home Prices

Updated Category News Views 217

Fannie Mae's Expert Insights on Home Price Trends A recent survey conducted by Fannie Mae proves insightful for those watching the housing market, as it sheds light on anticipated changes in home prices in the coming years. The report indicates that after an increase of 5.3% in 2024, experts expect a more moderate growth of approximately 2.4% for 2025 and 2.1% for 2026....

Continue Reading
PenKid Biomarker Revolutionizes Kidney Therapy Decisions

Updated Category News Views 31

The Emergence of PenKid in Critical Care You ever get the feeling that the old ways just aren’t cutting it anymore? That’s where this penKid news rolls in like a breath of fresh air. In the world of ICU management, especially with kidney replacement therapy (KRT), this little biomarker is flipping the script on traditional biomarkers. Imagine 1,436 critically ill...

Continue Reading